RNAZ - Rega marang bathi mangsa ngarep TransCode Therapeutics
The efficiency of RNA delivery into tumors and molecular stability determine the success of TransCode Therapeutics (RNAZ), as evidenced by the company's forward P/E ratio, which is currently fixed at 0.00. High expenditures in the absence of profit necessitate rigorous management of clinical trials. The development of a precision targeting system for metastases transforms this biotech firm into a key hub for combating incurable forms of cancer.
TransCode (RNAZ) - rincian metrik lan laporan keuangan
- nilai saham lan prakiraan konsensus rega:
- statistik kapitalisasi pasar:
- data ekuitas miturut neraca:
- rincian utang lan likuiditas:
Total Utang marang Modal TransCode Therapeutics|RNAZ - Rasio utang jangka dawa marang modal|Utang jangka cendhak marang modal TransCode Therapeutics|RNAZ - Utang kumulatif perusahaan|Utang marang nilai buku TransCode Therapeutics Inc.|RNAZ - Silihan lan utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan TransCode Therapeutics|Rasio cepet transcodetherapeutics.com
- statistik bathi lan rasio pasar:
RNAZ - Bathi pungkasan|Proyeksi bathi mangsa ngarep TransCode Therapeutics|RNAZ - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep TransCode Therapeutics|RNAZ - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA TransCode Therapeutics Inc.|RNAZ - Bathi operasional EBITDA|Bathi saben saham sajrone rolas wulan pungkasan TransCode Therapeutics|RNAZ - Bathi saben siji saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan transcodetherapeutics.com|RNAZ - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep TransCode Therapeutics
Analisis kabeh metrik perusahaan:TransCode Therapeutics, Inc. RNAZ
This indicator is calculated as the ratio of current market capitalization to projected net income, allowing for an assessment of the business's future value considering expected operating expenses. The trend of the calculated forward P/E for TransCode Therapeutics (RNAZ) reflects the company's ability to balance RNA therapy environmental safety costs and testing ethics with final profitability, signaling entry points or risks of inflationary pressure to the investor.
Pesaing langsung
Rega marang bathi mangsa ngarep Tempus Labs (TEM)|Qiagen NV - Rasio rega marang bathi mangsa ngarep|Rega marang bathi mangsa ngarep Ionis Pharma IONS|Kapitalisasi marang proyeksi bathi Repligen Inc. (RGEN)|Avidity Biosciences - Pangali Forward P/E|crisprtx.com (CRSP) - Prakiraan rega marang bathi|GeneDx (WGS) - Rega marang bathi mangsa ngarep|Rasio prakiraan rega marang bathi Ultragenyx Pharmaceutical Inc. (RARE)|BEAM (Beam Therapeutics Corp) - Pangali Forward P/E|Rasio rega marang bathi mangsa ngarep SRPT (Sarepta Corp)|Pangali Forward P/E TWST|TXG - Rasio prakiraan rega marang bathi|Intellia Therapeutics, Inc. - Prakiraan rega marang bathi|Pangali mangsa ngarep rega marang bathi STOK|BLFS: Prakiraan rega marang bathi|Wave Pharma - Rasio kapitalisasi marang bathi mangsa ngarep|MAZE: Pangali Forward P/E|sionnatx.com - Pangali mangsa ngarep rega marang bathi|PRME (Prime Medicine) - Pangali Forward P/E|Rasio prakiraan rega marang bathi Taysha Gene Therapies Inc TSHA|Rega marang bathi mangsa ngarep uniQure Corp (QURE)|MGTX (MeiraGTx Corp) - Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E RGNX (REGENXBIO Inc.)|Pangali Forward P/E solidbio.com SLDB|OCGN - Rega marang bathi mangsa ngarep|Rasio rega marang bathi sing dikarepake PACB|BNTC: Pangali Forward P/E|Rasio prakiraan rega marang bathi Design Corp (DSGN)|Prakiraan rega marang bathi RCKT|Pangali Forward P/E 4dmoleculartherapeutics.com|Prakiraan rega marang bathi LXEO (Lexeo Therapeutics)|Rasio kapitalisasi marang bathi mangsa ngarep KRRO|Pangali Forward P/E EDIT (Editas)|Kapitalisasi marang proyeksi bathi Silence Therapeutics Corp (SLN)|ProQR Therapeutics NV - Pangali Forward P/E|Codexis, Inc. (CDXS) - Prakiraan rega marang bathi|Sangamo Therapeutics, Inc. (SGMO) - Rega marang bathi mangsa ngarep|NAUT - Kapitalisasi marang proyeksi bathi|Rega marang bathi mangsa ngarep Metagenomi, Inc|DTIL: Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Generation Bio Co. (GBIO)|boundlessbio.com - Rasio rega marang bathi mangsa ngarep|Pangali Forward P/E XCUR (Exicure)|Pangali Forward P/E Imunon Inc IMNN|PHIO: Prakiraan rega marang bathi|Rasio rega marang bathi sing dikarepake MBIO|BNGO: Pangali Forward P/E|Rasio rega marang bathi mangsa ngarep APDN|Rega marang bathi mangsa ngarep bluebird bio|Rasio rega marang bathi mangsa ngarep IPA (ImmunoPrecise)|Pangali Forward P/E OMGA|Pangali Forward P/E Singular Genomics Corp (OMIC)|Regulus Therapeutics - Prakiraan rega marang bathi|Rasio kapitalisasi marang bathi mangsa ngarep SYRS (syros.com)|TBIO - Rega marang bathi mangsa ngarep|Pangali mangsa ngarep rega marang bathi TCON (TRACON Pharmaceuticals Inc.)|UBX: Pangali Forward P/E
